ROCKVILLE, Md., Aug. 1, 2023
/PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that
it will host one-on-one investor meetings at the 2023 Wedbush
PacGrow Healthcare Conference on Tuesday,
June 8, 2023.
2023 Wedbush PacGrow Healthcare
Conference
Date: Tuesday, August 8,
2023
About REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company
seeking to improve lives through the curative potential of gene
therapy. REGENXBIO's NAV Technology Platform, a proprietary
adeno-associated virus (AAV) gene delivery platform, consists of
exclusive rights to more than 100 novel AAV vectors, including
AAV7, AAV8 and AAV9. REGENXBIO and its third-party NAV Technology
Platform Licensees are applying the NAV Technology Platform in the
development of a broad pipeline of candidates, including late-stage
and commercial programs, in multiple therapeutic areas. REGENXBIO
is committed to a "5x'25" strategy to progress five AAV
Therapeutics from its internal pipeline and licensed programs into
pivotal-stage or commercial products by 2025.
Contact:
Investors:
Chris Brinzey
ICR Westwicke
339-970-2843
chris.brinzey@westwicke.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/regenxbio-announces-participation-at-the-2023-wedbush-pacgrow-healthcare-conference-301890876.html
SOURCE REGENXBIO Inc.